Status:
COMPLETED
Celebrex vs Tramadol in the Treatment of Chronic Lower Back Pain.
Lead Sponsor:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Conditions:
Back Pain
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
This study investigates if Celebrex is as effective as tramadol hydrochloride (Ultram) for patients with chronic low back pain, when administered over a 6-week period.
Eligibility Criteria
Inclusion
- The subject presents with duration of chronic low back pain of \> 3 months requiring regular use of analgesics (\> 4 days/week), except for acetaminophen which cannot have been the sole analgesic used.
Exclusion
- The subject has chronic low back pain, which is neurologic in etiology (i.e., radiculopathy, neuropathy, myelopathy)
Key Trial Info
Start Date :
March 1 2006
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
754 Patients enrolled
Trial Details
Trial ID
NCT00290901
Start Date
March 1 2006
Last Update
March 3 2021
Active Locations (54)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Phoenix, Arizona, United States
2
Pfizer Investigational Site
Scottsdale, Arizona, United States
3
Pfizer Investigational Site
Tucson, Arizona, United States
4
Pfizer Investigational Site
Little Rock, Arkansas, United States